Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats

Pharmacology

Volumn 79, Issue 1, 2007, Pages 17-26

  Kumar, A ^a   Naidu, P S ^a   Seghal, N ^a   Padi, S S V ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Alzheimer's disease; Antioxidant; Cognitive impairment; Colchicine; Oxidative stress; Red wine; Resveratrol

Indexed keywords

ACETYLCHOLINESTERASE; COLCHICINE; FREE RADICAL; GLUTATHIONE; MALONALDEHYDE; NITRITE; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN PROTECTION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; LONG TERM CARE; MALE; MAZE TEST; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ACETYLCHOLINESTERASE; ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BRAIN; COGNITION DISORDERS; COLCHICINE; GLUTATHIONE; INJECTIONS, INTRAVENTRICULAR; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMORY DISORDERS; NEUROPROTECTIVE AGENTS; NITRITES; OXIDATIVE STRESS; RATS; RATS, WISTAR; SPACE PERCEPTION; STILBENES; TUBULIN MODULATORS;

EID: 33845917602     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097511     Document Type: Article

References (50)

1. Pratico D: Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol 2002;63:563-567.
2. Moore AH, O'Banion MK: Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Deliv Rev 2002;54:1627-1656.
3. McKinney M, Coyle JT, Hedreen JC: Topographic analysis of the innervation of the neocortex and hippocampus by the basal forebrain cholinergic system. J Comp Neurol 1983;217:103-121.
4. Emerich DF, Walsh TJ: Cholinergic loss and cognitive impairment following intraventricular or intradentate injection of colchicine. Brain Res 1990;517:157-167.
5. Nakagawa Y, Nakamura S, Kase Y, Noguchi T, Ishihara T: Colchicine lesions in the rat hippocampus mimic the alterations of several markers of Alzheimer's disease. Brain Res 1987;408:57-64.
6. Nakayama T, Sawada T: Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacol Biochem Behav 2002;71:119-138.
7. Veerendra Kumar MH, Gupta YK: Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol Biochem Behav 2002;73:565-571.
8. Ceccatelli S, Ahlbom E, Diana A, Zhivotovsky B: Apoptosis in rat hippocampal dentate gyrus after intraventricular colchicine. Neuroreport 1997;8:3779-3783.
9. Slikkker W, Youdim MB, Palmer GC, Hall E, Williams C, Trembley B: The future of neuroprotection. Ann NY Acad Sci 1999;890:529-533.
10. Pervaiz S: Resveratrol: from grapevines to mammalian biology. FASEB J 2003;17:1975-1985.
11. Dartigues JF, Orgogozo JM: Wine consumption in the elderly. Ann Intern Med 1993;118:317-318.
12. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S, Breteler MB: Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997;153:185-192.
13. Martinez J, Moreno JJ: Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 2000;59:865-870.
14. Ozgova S, Hermanek J, Gut I: Different antioxidant effects of polyphenols on lipid peroxidation and hydroxyl radicals in the NADPH-, Fe-ascorbate- and Fe-microsomal systems. Biochem Pharmacol 2003;66:1127-1137.
15. Cao L, Wang YJ: Neuroprotection by resveratrol against cytotoxicity of oxidized low-density lipoprotein in PC12 cells (in Chinese). Zhonghua Yu Fang Yi Xue Za Zhi 2005;39:19-21.
16. Wang YJ, He F, Li XL: The neuroprotection of resveratrol in the experimental cerebral ischemia. Zhonghua Yi Xue Za Zhi 2003;83:534-536.
17. Mattson MP, Pedersen WA: Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int J Dev Neurosci 1998;16:737-753.
18. Verma A, Kulkarni SK: Evaluation of learning and memory mechanisms employing plus maze in rats and mice. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:117-125.
19. Frautschy SA, Hu W, Kim P, Miller SA, White-Harris ME, Chu T, Cole GM: Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol Aging 2001;22:993-1005.
20. Wills ED: Mechanism of lipid peroxide formation in animal. Biochem J 1966;99:667-676.
21. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
22. Green LC, Wagner DA, Glgowski J, Skipper PL, Wishnok JS, Tannebaum SR: Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Ann Biochem 1982;126:131.
23. Ellman GL, Courtney KD, Andres V, Featherstone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
24. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ: Protein measurement with Folin phenol reagent. J Biol Chem 1951;193:265-275.
25. Pasinetti GM, Aisen PS: Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998;87:319-324.
26. Ho L, Osaka H, Aisen PS, Pasinetti GM: Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol 1998;89:142-149.
27. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ: Microtubule interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK 1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 2002;275:14838-14845.
28. Matsumoto Y, Yamaguchi T, Watanabe S, Yamamoto T: Involvement of arachidonic acid cascade in working memory impairment induced by interleukin-1 beta. Neuropharmacology 2004;46:1195-1200.
29. Jain NK, Patil CS, Kulkarni SK, Singh A: Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide- induced cognitive dysfunction in mice. Behav Brain Res 2002;133:369-376.
30. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Moon RC, Pezzuto JM: Cancer chemoprotective activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-220.
31. Szewczuk LM, Forti L, Stivala LA, Penning TM: Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2. J Biol Chem 2004;279:22727-22737.
32. Johnson JL, Maddipati KR: Paradoxical effects of resveratrol on the two prostaglandin H synthases. Prostaglandins Other Lipid Mediat 1998;56:131-143.
33. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM: The red wine phenolics trans-resveratrol and resveratrol block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-219.
34. Subbaramaiah K, Chung WJ, Michaluarl P, Telang N, Tanabe T, Inove H, Jang M, Pezzuto JM, Dannenberg AJ: Resveratrol inhibits cycloxygenase-2 transcription and activity in phorbol ester treated human mammary epithelial cells. J Biol Chem 1998;273:21875-21882.
35. Yu Z, Cheng G, Hu B: Mechanism of colchicine impairment on learning and memory, and protective effect of CGP36742 in mice. Brain Res 1997;750:53-58.
36. Choi DW: Excitotoxic cell death. J Neurobiol 1992;23:1261-1275.
37. Leist M, Volbracht C, Kuhnle S, Fava E, Ferrando-May E, Nicotera P: Caspase-mediated apoptosis in neuronal excitotoxicity triggered by nitric oxide. Mol Med 1997;3:750-764.
38. Bondy SC: The relation of oxidative stress and hyperexcitation to neurological disease. Proc Soc Exp Biol Med 1995;208:337-345.
39. Bruce-Keller AJ, Li YJ, Lovell MA, Kraemer PJ, Gary DS, Brown RR, Markesbery WR, Mattson MP: 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J Neuropathol Exp Neurol 1998;57:257-267.
40. Shukitt-Hale B, Erat SA, Joseph JA: Spatial learning and memory deficits induced by dopamine administration with decreased glutathione. Free Radic Biol Med 1998;24:1149-1158.
41. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Alvarez D, Al-Dalain S, Martinez G, Leon OS, Springer JE: Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem 2003;86:545-555.
42. Pepicelli O, Fedele E, Bonanno G, Raiteri M, Ajmone-Cat MA, Greco A, Levi G, Minghetti L: In vivo activation of N-methyl-D-aspartate receptors in the rat hippocampus increases prostaglandin E (2) extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms. J Neurochem 2002;81:1028-1034.
43. Frankel EN, Waterhouse AL, Kinsella JE: Inhibition of human LDL oxidation by resveratrol. Lancet 1993;341:1103-1104.
44. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, Shi X: Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 2003;309:1017-1026.
45. Miller NJ, Rice-Evans CA: Antioxidant activity of resveratrol in red wine. Clin Chem 1995;41:1789.
46. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ: Microtubule interfering agents stimulate the transcription of cyclooxygenase-2: evidence for involvement of ERK 1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 2002;275:14838-14845.
47. Orallo F, Alvarez E, Camina M, Leiro JM, Gomez E, Fernandez P: The possible implication of trans-Resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol 2002;61:294-302.
48. Yen GC, Duh PD, Lin CW: Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res 2003;37:509-514.
49. Zhuang H, Kim YS, Koehler RC, Dore S: Potential mechanism by which resveratrol, a red wine constituent protects neurons. Ann NY Acad Sci 2003;993:276-286.
50. Sharma M, Gupta YK: Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002;71:2489-2498.